[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5582 Introduced in House (IH)]

<DOC>






115th CONGRESS
  2d Session
                                H. R. 5582

To direct the Secretary of Health and Human Services to conduct a study 
  and submit a report on barriers to accessing abuse-deterrent opioid 
 formulations for individuals enrolled in a plan under part C or D of 
                         the Medicare program.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 23, 2018

    Mr. Carter of Georgia (for himself, Mr. Loebsack, and Mr. Reed) 
 introduced the following bill; which was referred to the Committee on 
   Energy and Commerce, and in addition to the Committee on Ways and 
 Means, for a period to be subsequently determined by the Speaker, in 
   each case for consideration of such provisions as fall within the 
                jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To direct the Secretary of Health and Human Services to conduct a study 
  and submit a report on barriers to accessing abuse-deterrent opioid 
 formulations for individuals enrolled in a plan under part C or D of 
                         the Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited at the ``Abuse Deterrent Access Act of 
2018''.

SEC. 2. STUDY ON ABUSE-DETERRENT OPIOID FORMULATIONS ACCESS BARRIERS 
              UNDER MEDICARE.

    (a) In General.--Not later than 180 days after the date of the 
enactment of this Act, the Secretary of Health and Human Services shall 
conduct a study and submit to Congress a report on the adequacy of 
access to abuse-deterrent opioid formulations for individuals with 
chronic pain enrolled in an MA-PD plan under part C of title XVIII of 
the Social Security Act or a prescription drug plan under part D of 
such title of such Act, taking into account any barriers preventing 
such individuals from accessing such formulations under such MA-PD or 
part D plans, such as cost-sharing tiers, fail-first requirements, and 
prior authorization requirements.
    (b) Definition of Abuse-deterrent Opioid Formulation.--In this 
section, the term ``abuse-deterrent opioid formulation'' means an 
opioid with certain abuse-deterrent properties, such as physical or 
chemical barriers, agonist or antagonist combinations, aversion 
properties, delivery system mechanisms, or other features designed to 
prevent abuse of such opioid.
                                 <all>